The acquisition would help Merck strengthen its presence in the renal cell carcinoma space and support its cancer drug portfolio. U.S. pharmaceutical conglomerate, ...
Read More >>Sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic for the acute treatment of agitation Reports confirm that BioXcel Therapeu...
Read More >>A multi-centre phase-two study will represent the fourth clinical trial ongoing for Kazia’s GDC-0084 drug candidate Kazia Therapeutics Ltd, an Australian onco...
Read More >>GSK anticipates using Zymeworks’ Azymetric technology for developing bispecifics drugs that treat communicable diseases Zymeworks Inc, a clinical-stage biopha...
Read More >>Vertex would be paying $70 million in advance to work with Kymera including an equity investment in the company Kymera Therapeutics and Vertex Pharmaceuticals Incor...
Read More >>Roche, the leading Swiss pharma has pushed back its scheduled acquisition of the gene therapy specialist, Spark Therapeutics for third time in a row, as it waits for the U.S. government to complete regulatory review of...
Read More >>Condiments and sauce manufacturer Veeba Foods reportedly ventured into child nutrition segment with a new health beverage, V-Nourish. According to sources close to the matter, V-Nou...
Read More >>In May the drug received FDA breakthrough status and had lowered the risk of death for patients by 30% as compared to placebo The U.S. Food and Drug Administration ...
Read More >>FORTITUDE-ALS did not attain statistical importance in its primary endpoint of change from baseline in SVC Patients who received reldesemtiv in FORTITUDE-AL...
Read More >>The latest study will assess Apristor’s safety plus pharmacological profile in patients, besides the biomarker analyses, for exploring the drug’s predictive response factors. ...
Read More >>The leading American AAV-based genetic medicines company, Audentes Therapeutics Inc., has reportedly presented new positive data from ASPIRO, the AT132 Phase 1/2 clinical trial for the treatment of XLMTM (X-linked Myot...
Read More >>In a recent turn of events, Norton Healthcare and Select Medical have reportedly declared signing a joint venture agreement intended to assimilate outpatient rehabilitation solutions in the Southern Indiana and Louisville metro provinces. ...
Read More >>Bicycle Therapeutics, a biotech firm pioneering a new therapeutic class based on its patented bicyclic peptide or Bicycle® platform, and Oxurion have recently declared complete registration of Oxurion’s Phase...
Read More >>Precision is creating PBCAR0191 in partnership with Servier, a multinational pharmaceutical firm The company believes that the patien...
Read More >>BioTime Incorporation, a clinical stage biotechnology firm developing newfangled cellular treatments, has recently declared that updated outcomes from a Phase I/IIa clinical study of OpRegen®, its chief product can...
Read More >>Plenity is has been cleared for obese or overweight adults having a body mass index of at least 25 Reports confirm that the U.S. Food and Drug Administration (FDA) ...
Read More >>The data received to date is directionally correct and reduction in HBeAg and HBsAg have been observed in some individuals in both studies. U.S. based clinical-stag...
Read More >>Inscripta is working to develop a full suite of gene-editing tools (reagents, software and instruments) to increase the efficiency and speed of CRISPR-based gene-editing ...
Read More >>· The data was presented at the American Association for Cancer Research Annual Meeting 2019 · ...
Read More >>Clinical-stage biotechnology company Imvax, Inc., committed to creating novel patient-specific vaccines and immunotherapy strategies, has reportedly attained positive results from an ongoing Phase 1b clinical trial tha...
Read More >>Partners Healthcare has now become the first healthcare network to have the tool immediately available to doctors at the point-of-care in Massachusetts. Partners He...
Read More >>Nightstar’s agreement with Biogen will give the company the platform and resources it needs to expand its mission to restore sight in patients with inherited retinal diseases. ...
Read More >>The company is apparently looking to buy the electronic materials maker for bolstering its Performance Materials division Merck KGaA, the laboratory supplies provid...
Read More >>The fund would reportedly contribute toward disruptive scientific developments across a spate of therapeutic areas such as immunology, oncology, and neurosciences. ...
Read More >>The antibody, called as MTAU9937A, RO7105705, is also being assessed by Genentech in a different Phase 2 trial Anti-Tau monoclonal antibody was det...
Read More >>Council for Responsible Nutrition welcomed the action against companies that have tarnished consumer confidence for all legitimate products. The U.S. Food and Drug ...
Read More >>The building construction is scheduled to be completed in 2021 and is designed to offer office space, wet labs and a cafeteria. Merck, one of the leaders in the pha...
Read More >>The Torque-Thermo Fisher manufacturing facility is expected to come online by the end of 2019. Thermo Fisher Scientific Inc., the biotechnology products development...
Read More >>The new device possesses the potential to detect specific lung cancer markers at the earliest stage possible. In what may seem to a pathbreaking revolutionary finding i...
Read More >>The generic drug will mean low cost but high-quality drug access to people suffering from chronic respiratory and lung diseases. The U.S. Food and Drug Administrati...
Read More >>The news from Roche marks another failure in developing drugs for Alzheimer’s after many other drugmakers have stopped trials of prospective treatments. Roche...
Read More >>The deal links reimbursement for the blood thinner to the cardiovascular outcomes of patients. Sources familiar with the development ...
Read More >>Purdue Pharma L.P., the Connecticut-based pharmaceutical company, has reportedly announced that it has signed a partnership agreement with Alivio Therapeutics to advance one of its product candidates via clinical devel...
Read More >>U.K. biotech firm Abcam has recently confirmed the acquisition of Calico Biolabs, a specialist in rabbit monoclonal antibodies based out of California. Calico is known to provide custom, high-quality recombinant rabbit...
Read More >>The planned study would assess the efficacy, tolerability, and safety of the derazantinib-atezolizumab combination in patients with confirmed FGFR genomic aberrations and advanced urothelial cancer. ...
Read More >>© 2019 ReportsGO.com. All Rights Reserved.